The treatment landscape for advanced breast cancer has changed radically over the last 30-40 years with the refinement of surgical and radiographic techniques, approval of a range of chemotherapy regimens in the adjuvant and metastatic settings, and improvements in screening procedures. A deeper understanding of the molecular pathways underpinning tumor growth has led to the identification and development of a number of targeted therapies with particularly high activity in breast cancer. As an example, the prognosis of women with human epidermal growth factor receptor 2-positive (HER2þ) breast cancer has improved dramatically since the introduction of HER2-targeted therapies [1] . Meanwhile, in hormone receptor-positive (HRþ) breast cancer, the mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to be effective in combination with exemestane [2] .
Overall, these innovations have led to the earlier detection of breast cancers and better treatments, resulting in significant improvements in patient survival and quality of life. Finding future treatments for breast cancer will depend on gaining more insights into the pathways driving tumor growth and the mechanisms of acquired and de novo resistance. Investigational targeted agents currently in clinical development include the phosphatidylinositol 3-kinase (PI3K) inhibitor alpelisib (BYL719) and the cyclindependent kinase (CDK) 4/6 inhibitor ribociclib (LEE011).
Translating basic research into novel therapies in breast cancer
A thorough understanding of disease biology and patient needs lies at the heart of developing novel, effective therapies. Novartis has a long-standing heritage in developing treatment options for patients with breast cancer, targeting a range of oncogenic pathways-including the non-steroidal aromatase inhibitor letrozole and everolimus. Activation of the cyclin D-CDK4/6-inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway is common in breast cancer, and the efficacy of combined CDK4/6 inhibition with endocrine therapy has been demonstrated in the first-and secondline treatment of advanced breast cancer [3, 4] . These findings encouraged Novartis to expedite the development of ribociclib (LEE011), an orally bioavailable, selective, ATP-competitive inhibitor of CDK4/6 ( Figure 1 ) [5] . In preclinical studies, ribociclib demonstrated high levels of growth inhibition in HRþ breast cancer cell lines [6] . Additionally, in xenograft models of HRþ breast cancer, ribociclib demonstrated synergistic antitumor activity in doublet combinations with endocrine therapies including fulvestrant and letrozole [6] . In the first-in-human Phase 1 trial of adult patients with advanced solid tumors or lymphoma, singleagent ribociclib displayed promising signs of clinical activity; of 31 patients, 9 experienced stable disease and 1 patient had a partial response [5] . Ribociclib clinical development rapidly progressed from early-phase single-agent and dose-finding doublet combination trials to the recent Phase 3 MONALEESA-2 trial based on Phase 1 preliminary data indicating the absence of a drug-drug interaction between ribociclib and letrozole in the CLEE011X2107 trial [7] ; frequent Data Monitoring Committee meetings mitigated any potential risk. The efficacy and safety of ribociclib is now being investigated in a number of other Phase 3 trials in different patient populations and therapy combinations (Table 1) . In March 2017, ribociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of postmenopausal women with HRþ, HER2À advanced or metastatic breast cancer was approved by the US Food and Drug Administration (FDA), based on positive results from the planned interim analysis of MONALEESA-2 (discussed below) [8] . In addition, based on preclinical data with ribociclib in combination with endocrine therapies and PI3K inhibitors, a series of ongoing Phase 1 and 2 trials are investigating triplet therapy combinations in HRþ breast cancer [9] [10] [11] .
Community approach to clinical trials: MONALEESA-2 case study
Novartis' strong collaboration with clinicians at trial sites across the world supports fast, efficient, and appropriate patient recruitment onto clinical trials. This was exemplified by the rapid completion of the MONALEESA-2 trial. In MONALEESA-2, the first patient was randomized in January 2014 with enrollment completed after $14 months (March 2015); the planned interim analysis was performed after $24 months (January 2016). Positive interim results showed that the trial met its primary endpoint, leading to the recommendation by the Independent Data Monitoring Committee to stop the trial early (May 2016). This was followed by the US FDA granting Breakthrough Therapy designation after around 31 months (August 2016), granting Priority Review three months later (November 2016), followed by approval for first-line ribociclib in combination with aromatase inhibitor therapy 5 months later (March 2017). This represents a rapid development timeline from first patient enrollment to trial read-out, considering the median duration of Phase 3 oncology trials in 2014 was $50 months [12] .
Completion of MONALEESA-2 was supported by several key trial design elements. First, a large study steering committee was consulted on the design and conduct of the study; the globally distributed steering committee aided in the consideration of local regulatory requirements and fostered effective inter-investigator communication, resulting in efficient trial conduct with high regional participation. In total, 668 patients were enrolled at 223 sites, across 29 countries worldwide. Second, recruitment was facilitated by permitting patients who had received 14 days of prior letrozole or anastrozole onto the trial, increasing the potential pool of eligible patients. Finally, the interim analysis for MONALEESA-2 was planned after 211 PFS events (70% of the planned 302 events), providing an early but mature look at the trial data. The chosen timing of interim analysis and the prespecified efficacy criteria were guided by early discussions with health authorities, and supported by previous experience in the BOLERO-2 trial [2] , enabling a stable and robust assessment of treatment effect prior to final analysis. In MONALEESA-2, a stringent Haybittle-Peto type boundary ensured that early trial declaration of superiority would only occur if the HR was 0.56 with P < 0.0000129 [8] . Rigorous statistical testing procedures are also in place for the secondary endpoint of overall survival. Similar testing strategies are being employed throughout the ribociclib development program; by implementing robust statistical criteria for interim analyses, data can potentially be analyzed early for superior efficacy, allowing expedited regulatory filings and, if approved, for patients to benefit from novel therapies at the earliest possible opportunity.
Ribociclib in other patient populations
Novartis is also taking an innovative approach to investigating ribociclib in under-served indications that have not been previously investigated with other CDK4/6 inhibitors. Key trials include the following:
MONALEESA-3 (NCT02422615), which is investigating ribociclib in combination with fulvestrant in men (as well as postmenopausal women) with HRþ/HER2À advanced breast cancer in the first-and second-line settings. This trial was designed in part to anticipate the results from the Phase 3 FALCON study investigating fulvestrant vs anastrozole for the first-line treatment of HRþ advanced breast cancer. The first patient was enrolled onto MONALEESA-3 in June 2015, and enrollment was completed in May 2016. MONALEESA-7 (NCT02278120), which is investigating ribociclib in combination with a non-steroidal aromatase inhibitor or tamoxifen plus goserelin in pre-and perimenopausal women with HRþ/HER2À advanced breast cancer, in the first-line setting. The first patient was enrolled in November 2014, and enrollment was completed in August 2016.
TRINITI-1 (NCT02732119), which is investigating ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HRþ/HER2À advanced breast cancer who have progressed on a prior endocrine therapy and CDK4/6 inhibitor. Recruitment onto this trial is ongoing.
The ribociclib development program therefore includes a wide range of patients. As well as postmenopausal women, the MONALEESA trials include pre-and perimenopausal patient populations, in the first-and later-line settings (as well as specifically in the post-CDK4/6 inhibitor setting); and are also investigating men with advanced breast cancer, who remain a rare and under-served population.
The Novartis pipeline in breast cancer includes a number of promising compounds currently undergoing Phase 1-3 clinical trials, across the full range of breast cancer subtypes (HRþ/ HER2À, HER2þ, and triple-negative breast cancer). In addition to ribociclib, other key Phase 3 compounds include PI3K/mTOR pathway inhibitors.
